Abstract
Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell targeting therapies. Thus, agents that can reprogram macrophages towards a proinflammatory state hold promise as novel immunotherapies for solid cancers. Here, we report that immunotherapeutic targeting of the macrophage scavenger receptor Clever-1 in heavily pretreated metastatic cancer patients was able to induce a significant increase and activation of peripheral T-cells. Anti-Clever-1 (FP-1305) administration led to suppression of nuclear lipid signaling pathways and a proinflammatory phenotypic switch in blood monocytes. Mechanistically, Clever-1 inhibition impaired multiprotein vacuolar ATPase–mediated endosomal acidification and improved macrophage cross-presentation of scavenged antigens. Our results reveal a non-redundant role played by the receptor Clever-1 in suppressing adaptive immune cell activation in humans. We provide evidence that targeting macrophage scavenging activity can promote an immune switch potentially leading to intratumoral proinflammatory responses in metastatic cancer patients.
Competing Interest Statement
SJ, MKK, JM and MH own shares of Faron Pharmaceuticals. MH reports receiving funding from Faron for the preclinical development of anti-Clever-1 mAbs. SS, PB and MH have received consultancy fees from Faron. PB reports (outside the submitted work) honoraria from Bristol-Myers Squibb, MSD, Pfizer, Novartis, Oncorena, TILT Biotherapeutics, Ipsen, EUSA and Herantis Pharma, and stock ownership: TILT Biotherapeutics and Terveystalo.
Clinical Trial
NCT03733990
Funding Statement
This study was funded by the Academy of Finland (AT, TL, SJ and MH), Emil Aaltonen Foundation (RV), Sigrid Juselius Foundation (MH), and the Finnish Cancer Foundations (MH). Faron Pharmaceuticals sponsored the MATINS trial.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This multi-institutional, first in-human, open-label, non-randomized phase I, dose escalation study was approved by local institutional review boards. The Institutional Review Boards were as follows: (Country, Name of the ethics committee, Decision) Finland, The Ethical Committee of North Ostrobothnias Hospital District, Approved; United Kingdom, West Midlands - Edgbaston Research Ethics Committee, Health Research Authority, Approved; The Netherlands, Medical Ethical Review Committee Erasmus MC, Approved. All participating patients signed informed consent. A written informed consent was obtained from healthy donors donating cells. The collection was approved by the Ethics Committee Hospital District of Southwest Finland. The samples were kept anonymous and handled according to the ethical guidelines set by the University of Turku.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Material requests should be addressed to Maija Hollmen, maijal@utu.fi. FP-1305 is a proprietary-owned antibody of Faron Pharmaceuticals. Requests for this should be addressed to Jami Mandelin, jami.mandelin@faron.com.
